NONO
Clinical-stage biotechnology company focused on developing peptide-based inhibitors of PSD-95 for neuroprotection and neurorestoration. Activities include preclinical validation, IND-enabling studies, global randomized clinical trials in acute ischemic stroke, regulatory strategy, and CMC/clinical supply operations. Development programs target acute ischemic stroke (intravenous and pre-hospital administration), thrombolytic-compatible protease-resistant peptides, and subcutaneous formulations for subacute/chronic neurological indications.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Intravenous PSD-95 inhibitor — 20 amino-acid peptide (lead IV candidate)
A 20–amino-acid peptide designed for intravenous infusion to reduce ischemic brain injury and improve functional outcomes when administered in the acute phase of ischemic stroke; evaluated in global Phase 3 studies.
Protease-resistant PSD-95 inhibitor — thrombolytic-compatible analog
Next-generation protease-resistant peptide analogs engineered to retain plasma exposure when co-administered with thrombolytic agents, enabling compatibility with standard-of-care clot-dissolving therapies.
Subcutaneous long-acting PSD-95 inhibitor formulation
Subcutaneous formulation intended for rapid onset and extended action to enable outpatient or non-hospital administration for subacute and chronic neurological conditions including stroke recovery and dementia-related indications.
Nerinetide
NoNO's lead compound for people experiencing an ischemic stroke, currently completing its global Phase 3 program in people not previously treated with a clot dissolving drug.
StrokePen
With NoNO42 in Phase 1, for use alongside clot dissolving drugs for all people experiencing ischemic stroke.
NoNO-SC
Administered subcutaneously with rapid onset and long action to enable the treatment of subacute and chronic neurological conditions outside of medical settings by anyone – anywhere.
Intravenous PSD-95 inhibitor — 20 amino-acid peptide (lead IV candidate)
A 20–amino-acid peptide designed for intravenous infusion to reduce ischemic brain injury and improve functional outcomes when administered in the acute phase of ischemic stroke; evaluated in global Phase 3 studies.
Protease-resistant PSD-95 inhibitor — thrombolytic-compatible analog
Next-generation protease-resistant peptide analogs engineered to retain plasma exposure when co-administered with thrombolytic agents, enabling compatibility with standard-of-care clot-dissolving therapies.
Subcutaneous long-acting PSD-95 inhibitor formulation
Subcutaneous formulation intended for rapid onset and extended action to enable outpatient or non-hospital administration for subacute and chronic neurological conditions including stroke recovery and dementia-related indications.
Nerinetide
NoNO's lead compound for people experiencing an ischemic stroke, currently completing its global Phase 3 program in people not previously treated with a clot dissolving drug.
StrokePen
With NoNO42 in Phase 1, for use alongside clot dissolving drugs for all people experiencing ischemic stroke.
NoNO-SC
Administered subcutaneously with rapid onset and long action to enable the treatment of subacute and chronic neurological conditions outside of medical settings by anyone – anywhere.
Services
Design and conduct of multicentre Phase 1–3 clinical trials for peptide neurotherapeutics, including trial operations, site coordination, safety monitoring, and endpoint assessment.
Preclinical pharmacology, efficacy in animal models, and IND-enabling studies to support clinical translation of CNS peptide therapeutics.
Design and conduct of multicentre Phase 1–3 clinical trials for peptide neurotherapeutics, including trial operations, site coordination, safety monitoring, and endpoint assessment.
Preclinical pharmacology, efficacy in animal models, and IND-enabling studies to support clinical translation of CNS peptide therapeutics.
Expertise Areas
- Clinical trial management (global Phase 1–3)
- Peptide therapeutics development
- Neuroprotection and neurorestoration
- Stroke therapeutics and endovascular thrombectomy pathways
Key Technologies
- PSD-95 inhibition (protein–protein interaction blockade)
- Peptide therapeutic design and protease-resistant modification
- Blood–brain barrier delivery of peptide agents
- Protease-resistance chemistry
News & Updates
Announcement of first participant dosed in a Phase 1 single ascending dose study evaluating a thrombolytic-compatible protease-resistant peptide for acute ischemic stroke.
Publication describing next-generation protease-resistant peptide inhibitors designed to resolve drug–drug interactions with thrombolytics and extend therapeutic potential in acute ischemic stroke.
Announcement of enrollment initiation for a global Phase 3 randomized trial evaluating peptide therapy in acute ischemic stroke patients selected for endovascular thrombectomy without prior thrombolysis.
Publication and presentation of ESCAPE-NA1 Phase 3 results showing improved outcomes in the subgroup of patients who did not receive thrombolytic therapy, with associated pharmacokinetic findings on thrombolytic interaction.
Company announcement that enrollment was completed for two Phase 3 studies including a pre-hospital study and a trial focused on endovascular thrombectomy patients.
Multiple media articles and industry coverage discussing the potential implications of the company's stroke trial results and development program.
Announcement of first participant dosed in a Phase 1 single ascending dose study evaluating a thrombolytic-compatible protease-resistant peptide for acute ischemic stroke.
Publication describing next-generation protease-resistant peptide inhibitors designed to resolve drug–drug interactions with thrombolytics and extend therapeutic potential in acute ischemic stroke.
Announcement of enrollment initiation for a global Phase 3 randomized trial evaluating peptide therapy in acute ischemic stroke patients selected for endovascular thrombectomy without prior thrombolysis.
Publication and presentation of ESCAPE-NA1 Phase 3 results showing improved outcomes in the subgroup of patients who did not receive thrombolytic therapy, with associated pharmacokinetic findings on thrombolytic interaction.
Company announcement that enrollment was completed for two Phase 3 studies including a pre-hospital study and a trial focused on endovascular thrombectomy patients.
Multiple media articles and industry coverage discussing the potential implications of the company's stroke trial results and development program.